Rare Gastrointestinal Diseases Market Expansion

The Rare Gastrointestinal Diseases Treatment Market is set to grow at a CAGR of 4.0%, reaching $2.63 billion by 2030. Key factors driving this growth include genomic sequencing, precision medicine, biologics and gene therapies, telemedicine, and AI-powered algorithms. Additionally, increasing disease awareness, advancements in medical research, rising healthcare expenditure, and government initiatives are contributing to market growth. Key players in the market include Takeda Pharmaceutical Company Limited, Vertex Pharmaceuticals, Shire (now part of Takeda), Amicus Therapeutics, Ipsen, and Sarepta Therapeutics.